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Abstract
Case reports indicate that psychiatrists administered  3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recrea-
tional use of MDMA as ‘Ecstasy’ resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating
MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder, refractory to both psychotherapy and psychopharmacology,
were randomly assigned to psychotherapy with concomitant active drug (n¼12) or inactive placebo (n¼8) administered during two 8-h experimental
psychotherapy sessions. Both groups received preparatory and follow-up non-drug psychotherapy. The primary outcome measure was the Clinician-
Administered PTSD Scale, administered at baseline, 4 days after each experimental session, and 2 months after the second session. Neurocognitive
testing, blood pressure, and temperature monitoring were performed. After 2-month follow-up, placebo subjects were offered the option to re-enrolli n
the experimental procedure with open-label MDMA. Decrease in Clinician-Administered PTSD Scale scores from baseline was significantly greater for the
group that received MDMA than for the placebo group at all three time points after baseline. The rate of clinical response was 10/12 (83%) in the active
treatment group versus 2/8 (25%) in the placebo group. There were no drug-related serious adverse events, adverse neurocognitive effects or clinically
significant blood pressure increases. MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of
harm, and it may be useful in patients refractory to other treatments.
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Introduction
Posttraumatic stress disorder (PTSD) is a debilitating anxiety
disorder characterized by re-experiencing, hyperarousal and
avoidance symptoms, and is a major worldwide public health
problem. The high incidence of PTSD and the limited eﬀec-
tiveness of existing treatments combine to create an urgent
need for the development of new treatments. In the United
States, the lifetime prevalence of PTSD in the general popu-
lation is between 6% and 10% (Kessler et al., 2005), and is
much higher in countries where there is endemic armed con-
ﬂict (de Jong et al., 2003; Thabet and Vostanis, 1999; Weine
et al., 1995). In US soldiers returning from service in Iraq
and/or Afghanistan, the incidence of PTSD is as high as
18% (Hoge et al., 2004), and it is estimated that those with
PTSD will number between 75,000 and 225,000 (Tanielian
and Jaycox, 2008). PTSD is typically a chronic illness
(Breslau and Davis, 1992; Kessler et al., 2005) associated
with high rates of psychiatric and medical comorbidity,
disability, suﬀering, drug abuse, and suicide (Breslau, 2001;
Cohen et al., 2009; Frayne et al., 2004; Kessler et al., 2005;
Perkonigg et al., 2000).
Existing treatments for PTSD include both pharmacother-
apy and psychotherapies. Although a variety of drugs are
used to treat symptoms of PTSD, they have limited eﬃcacy.
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jop.sagepub.comTo date, the selective serotonin reuptake inhibitors (SSRIs)
sertraline and paroxetine are the only two drugs approved by
the Food and Drug Administration (FDA) for this indication
(Brady et al., 2000; Marshall et al., 2001). Nine clinical trials
of SSRIs for PTSD published between 1994 and 2007 dem-
onstrated a mean between-group eﬀect size (Cohen’s d)o f
0.5 for drug eﬀect compared with placebo (Foa et al.,
2009). After identifying 22 individual drugs in seven diﬀerent
drug classes, a 2008 review of PTSD treatment studies by the
Institute of Medicine was inconclusive regarding evidence for
use of any of the drugs studied (Committee on Treatment of
Posttraumatic Stress Disorder, 2008). Other recent reviews of
the literature have reached more favorable conclusions about
pharmacotherapy. Several meta-analyses found that, while
some studies did not show a signiﬁcant drug eﬀect, in general
the response rate to pharmacotherapy was 20–22% greater
than the response to placebo, and in SSRI trials 30% of sub-
jects can achieve complete remission at 12 weeks. All these
reviews have emphasized the need for further research into
more eﬀective agents for PTSD (Foa et al., 2009; Ipser et al.,
2006; Stein et al., 2009; Ursano et al., 2004).
The most widely recognized methods of psychotherapy
for PTSD are cognitive behavioral therapy (particularly
Prolonged Exposure and Cognitive Processing Therapy),
Eye Movement Desensitization and Reprocessing (EMDR),
and psychodynamic psychotherapy (Foa et al., 2009; Ursano
et al., 2004). A recent meta-analysis of direct comparison
studies of ‘bona ﬁde psychotherapies’ concluded that there
is no statistically signiﬁcant diﬀerence in between-group
eﬀect size (Benish et al., 2008). A review of cognitive behav-
ioral therapy for PTSD listed 107 studies (Foa et al., 2009). Of
the 36 studies using the Clinician-Administered PTSD Scale
(CAPS) as an outcome measure and intent-to-treat analysis,
the mean eﬀect size was 0.88 when compared against wait-list
controls (Foa et al., 2009). In clinical trials of psychotherapy
for PTSD, the dropout rate is typically 20–30%, and the
response rate is between 60% and 95% among subjects who
receive active treatment and complete the trials (Cloitre,
2009; Hembree et al., 2003; Rothbaum et al., 2006). Data
about combined psychotherapy and pharmacotherapy are
limited to a few small studies with mixed results (Foa et al.,
2009; Davis et al., 2006; Rothbaum et al., 2006). Overall, the
evidence for pharmacotherapy and psychotherapies in the
above studies indicates that existing therapies for PTSD are
ineﬀective for between 25% and 50% of patients who enroll
in clinical trials. An eﬀective treatment that could reduce the
substantial treatment failure rates associated with existing
PTSD treatments is needed.
Methylenedioxymethamphetamine (MDMA) is a ring-
substituted phenylisopropylamine derivative with a unique
proﬁle of psychopharmacological eﬀects. MDMA was pat-
ented in 1914 by the German chemical and pharmaceutical
company Merck KGaA as an intermediate compound in the
synthesis of other drugs (Benzenhoefer and Passie, 2006;
Freudenmann et al., 2006). Before MDMA was classiﬁed in
the United States as a Schedule I controlled substance in
1985, a number of psychiatrists and other therapists in the
United States and Europe used MDMA as an adjunct to
psychotherapy. MDMA was reported to decrease feelings
of fear while maintaining a clear-headed, alert state of
consciousness (Greer and Tolbert, 1998). More recently,
Phase I clinical trials have demonstrated that MDMA can
be administered without evidence of harm to pre-screened
subjects, and induces a 2–4-h experience typically character-
ized by euphoria, increased well being, sociability, self-conﬁ-
dence, and extroversion (Cami et al., 2000; Harris et al.,
2002; Kolbrich et al., 2008; Liechti et al., 2001; Tancer and
Johanson, 2001; Vollenweider et al., 1998). To test the poten-
tial eﬃcacy of the clinical use of MDMA, we present the ﬁrst
rigorous data on its therapeutic application in this pilot Phase
II clinical trial.
The decreased fear response induced by MDMA adminis-
tration may be useful in the treatment of PTSD, a condition
that involves exaggerated and uncontrolled fear responses.
Many psychotherapies for PTSD involve the induction and
extinction of these abnormal autonomic responses through
revisiting traumatic experiences in psychotherapy with an
appropriate level of emotional engagement (Foa et al.,
2009). Frequently, however, treatment may be ineﬀective
when patients are unable to tolerate feelings associated
with revisiting the trauma, or when emotional numbing
during exposure to traumatic memories precludes a level of
engagement necessary for extinction (Jaycox and Foa, 1999).
Therefore, if a drug could temporarily reduce fear and
increase interpersonal trust, without clouding the sensorium
or inhibiting access to emotions, it might prove an eﬀective
catalyst to psychotherapy for PTSD. The use of drugs to
catalyze psychotherapy has been discussed in the psychiatric
literature since the 1940s and has included the use of barbi-
turates, amphetamines, nitrous oxide, LSD, and others
(Sargent et al., 1972). This report contains ﬁndings from the
ﬁrst completed pilot study designed to explore the possibility
that MDMA could serve as such a catalyst. The hypothesis
tested is that MDMA could be administered without harm to
people with chronic, treatment-resistant PTSD and, in con-
junction with psychotherapy, would lead to a signiﬁcant
decrease in PTSD symptoms compared with the same psycho-
therapy in conjunction with inactive placebo.
Possible mechanisms
Several possible mechanism of action for MDMA-assisted
psychotherapy can be postulated. Learning theory, emotional
processing theory and social-cognitive theories aimed at
explaining the therapeutic eﬀects of exposure therapy have
been summarized by Foa et al. (Foa et al., 2009). To be eﬀec-
tive, exposure must be accompanied by a degree of emotional
engagement or ‘fear activation’ while avoiding dissociation or
overwhelming emotion (Foa et al., 2007). This has been
referred to as working within the ‘optimal arousal zone’ or
‘window of tolerance’ (Ogden and Pain, 2006; Siegel, 1999;
Wilbarger and Wilbarger, 1997). Patients with PTSD are
prone to extremes of emotional numbing or overwhelming
anxiety, and often have a narrow window between thresh-
olds of under and over-arousal (Ogden and Pain, 2006).
MDMA may exert its therapeutic eﬀect by widening this
window. If MDMA allows patients to stay emotionally
engaged without being overwhelmed by anxiety while revisit-
ing traumatic experiences, it may thereby catalyze eﬀective
exposure therapy.
440 Journal of Psychopharmacology 25(4)The pharmacological eﬀects of MDMA include serotonin
release, 5HT2 receptor stimulation, and increase in levels of
the neurohormones oxytocin, prolactin and cortisol (Dumont
et al., 2009; Grob et al., 1996; Harris et al., 2002; Mas et al.,
1999; Thompson et al., 2007; Wolﬀ et al., 2006). Serotonin
release plays an important role in producing the subjective
eﬀects of MDMA (Farre et al., 2007; Liechti et al., 2000;
Liechti and Vollenweider, 2000; Tancer and Johanson,
2007). Pretreatment with SSRIs reduces most acute subjective
and physiological eﬀects of MDMA, including eﬀects on
mood and perception. Serotonin release directly or indirectly
leads to an elevation in oxytocin, possibly by stimulating
5HT1A receptors (Baggott et al., 2008; Dumont et al., 2009;
Thompson et al., 2007). Recent ﬁndings suggest that oxytocin
is involved in aﬃliation, trust and accurate perception of
emotion (Domes et al., 2007; Kirsch et al., 2005; Zak et al.,
2005), so elevated oxytocin might help participants form a
therapeutic alliance and revisit traumatic experiences in an
emotionally engaged state. In human volunteers, oxytocin
reduces activation of the amygdala in response to fear-indu-
cing stimuli (Kirsch et al., 2005) and increases trust
(Baumgartner et al., 2008; Kosfeld et al., 2005). A recent
study reported that elevation in oxytocin after MDMA was
associated with greater sociability and gregariousness
(Dumont et al., 2009). It has been postulated that prolactin
release following MDMA administration may contribute to
a post-orgasmic-like sense of relaxation and receptivity
(Passie et al., 2005). The extent to which each of these phar-
macological mechanisms may play a role in possible thera-
peutic eﬀects of MDMA is speculative.
The ‘neurocircuitry model’ of PTSD postulates a deﬁcit in
extinction of fear conditioning mediated by the amygdala and
the ventral/medial prefrontal cortex (vmPFC) (Rauch et al.,
2006), a model supported by ﬁndings of reduced hippocampal
activity and volume, increased activity in the amygdala and
decreased activation of the medial prefrontal cortex in people
with PTSD (Rauch et al., 2006). A human Positron Emission
Tomography (PET) study 75min following MDMA admin-
istration has shown increases in cerebral blood ﬂow in the
ventromedial frontal and occipital cortex, and decreases in
the left amygdala (Gamma et al., 2000). MDMA may pro-
duce some of its eﬀects through these acute changes in brain
activity, possibly reversing abnormalities known to be associ-
ated with PTSD and thereby allowing for eﬀective processing
of traumatic material during the therapy sessions.
Methods and materials
Subjects
Subjects were recruited via letters to psychotherapists and
internet advertisements. Potential subjects aged 21–70 years
were screened using a scripted telephone interview to identify
previously diagnosed medical or psychiatric exclusion
criteria. Candidates who passed telephone screening and
gave informed consent were evaluated in an outpatient
oﬃce by an independent rater and a physician. Of these,
20 met all enrollment criteria and were recruited for the
study, with replacement of two dropouts (Figure 1). For
this initial pilot study, a minimum sample size of eight per
group with oversampling for the experimental group was
determined adequate to produce useful estimates of eﬀect
size. The study was approved by the Copernicus Group
Independent Review Board (IRB), Research Triangle Park,
NC, USA, and was conducted according to their regulatory
guidance for protection of human subjects and relevant
Federal regulations and international standards. Written
informed consent was obtained from each subject by the
investigators. Capacity to give informed consent was assessed
clinically and with a written quiz testing understanding of
the consent document. Enrollment began in March 2004
and ended in January 2008. Follow-up was completed in
September 2008.
MDMA
The MDMA used was from a supply produced by David
E Nichols, PhD, for the sponsor, which holds an FDA
Drug Master File and Investigational New Drug permit
(IND) for the study drug.
Design
After enrollment, subjects were randomized, in double-blind
fashion, to receive two experimental sessions of either
psychotherapy with concomitant MDMA administration
or the same psychotherapy accompanied by inactive placebo
(lactose) administration (psychotherapy-only). The blind was
broken for each subject after the follow-up visit 2 months
after the second experimental session. All subjects who ini-
tially received placebo were oﬀered participation in an open-
label crossover segment (‘Stage 2’) (Figure 2). After the
2-month follow-up, nine subjects were given a third session
of MDMA with psychotherapy, as allowed in a protocol
amendment. However, because not all subjects received a
third session and placebo subjects received only two sessions,
data related to the third session were omitted from analysis,
and for simplicity are omitted from Figure 2.
Subjects were required to taper and abstain from all psy-
chotropic medication during study participation except seda-
tive hypnotics or anxiolytics used as-needed between MDMA
or placebo sessions (referred to as ‘rescue medications’). After
preliminary evidence of safety and eﬃcacy had been estab-
lished, a protocol amendment was approved allowing the last
nine subjects to receive a supplemental dose of MDMA or
placebo in all experimental sessions. The purpose of this sup-
plemental dose, half the initial dose administered 2h after-
wards, was to prolong the therapeutic window of MDMA
eﬀects and gather pilot data about dose for design of future
clinical trials.
Assessments
Study entry screening consisted of a Structured Clinical
Interview for Axis I Diagnosis (SCID) (First et al., 1994),
the SCID II for personality disorder (First et al., 1997),
CAPS, medical history, physical examination, serum chemis-
try proﬁle, complete blood count, thyroid-stimulation hor-
mone (TSH), free thyroxine, HIV serology, urinalysis, and
electrocardiogram (ECG). Subjects were required to meet
Mithoefer et al. 441DSM-IV-R criteria for the diagnosis of crime or war-related
chronic PTSD, and to have treatment-resistant symptoms,
deﬁned as a CAPS score of  50 (signifying moderate
to severe symptoms) following at least 3 months of prior
SSRI or serotonin–norepinephrine reuptake inhibitor
(SNRI) treatment in addition to at least 6 months of psycho-
therapy. Exclusion criteria required freedom from any major
medical conditions. In addition, psychiatric exclusion criteria
included Borderline Personality Disorder or any current Axis
I disorder with the following exceptions which were allowed:
anxiety disorders, aﬀective disorders other than bipolar dis-
order type 1, substance abuse or dependence in remission for
 60 days, and eating disorder without active purging. Urine
drug testing for cocaine, marijuana, amphetamines, MDMA,
opiates and benzodiazepines was performed during initial
screening and immediately before each experimental session.
All screens were negative in all subjects.
Outcome measures
Primary. The CAPS is a widely used structured interview for
quantifying PTSD symptoms that has excellent psychometric
properties of reliability and validity (Weathers et al., 2001).
This measure produces a global symptom severity score as
well as a categorical ranking as to whether or not a subject
meets DSM-IV-R criteria for PTSD.
Secondary. Impact of Events Scale-Revised (IES-R) is a
widely used self-report measure that assesses psychological
response to stress. It was revised to parallel the DSM-IV cri-
teria for PTSD and found to have acceptable psychometric
properties (Weiss, 1997). The Symptom Checklist 90-Revised
(SCL-90-R) is a self-report of symptoms covering a wide
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Figure 1. Flow Diagram.
442 Journal of Psychopharmacology 25(4)range of psychiatric categories and yielding nine symptom
scales as well as global indices (Derogatis, 1994).
Neurocognitive measures
The Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) tests attention and
processing speed, expressive language, visual-spatial and
constructional abilities, and memory (Randolph et al.,
1998). The Paced Auditory Serial Addition Task (PASAT)
assesses information processing speed and mental ﬂexibility
(Gronwall, 1977). The Rey-Osterrieth Complex Figure
(RCFT) assesses visuospatial memory associated with a vari-
ety of neurological conditions that alter eﬀective brain func-
tion (Mirushina et al., 1999).
Physiological measures
Blood pressure, pulse, and temperature were monitored
during all experimental sessions.
Randomization and blind – Stage 1
Subjects were randomized to either MDMA or placebo, in
conjunction with psychotherapy, in a ratio of 60%
MDMA (n¼12) to 40% placebo (n¼8), replacing drop-
outs to preserve the group-assignment ratio and double-
blinding. On the day of each subject’s ﬁrst experimental
session, an independent randomization monitor assigned
a bottle containing either MDMA or placebo, deter-
mined by a computer-generated randomization list. The
subjects, investigators and the independent rater who
administered the outcome measures were all blinded. The
independent rater did not have access to records of treat-
ment sessions.
After screening and enrollment, participants completed
baseline psychological and neurocognitive measures.
Outcome measures were repeated approximately 4 days
after each of two 8-h experimental sessions and 2 months
after the second experimental session. Participants com-
pleted neurocognitive measures at baseline and again
2 months after the second experimental session (Table 1).
Stage 2
Placebo subjects who enrolled in the open-label arm com-
pleted outcome measures 2 months after their last experimen-
tal session. The schedule of visits in Stage 2 was nearly
identical to the schedule in Stage 1 (Table 1).
Therapeutic intervention
The study was conducted in a comfortable, aesthetically
pleasing outpatient oﬃce with facilities for the subject and a
blinded consultant nurse to remain at the site overnight.
The investigators maintained equipment and drugs for treat-
ment of medical emergencies, and an emergency physi-
cian and nurse were on site for all experimental sessions.
The experimental sessions lasted 8–10h, followed by an over-
night stay. One of the investigators maintained daily
Study visit
Stage l-double blind
Informed consent and initial
screening
SCID, CAPS, IES, SCL-90-R
Neuropsychological measures
Physical exam, blood tests,
EKG
Two 90 minute introductory
sessions with therapists
All day MDMA or placebo
experimental session
Spending night in clinic with
nurse on duty
Daily phone contact for a week
Repeat CAPS, IES & SCL-90-R
4 days after
experimental session
Repeat CAPS, IES & SCL-90-R
and neuropsychological
measures 2 months after 2nd
experimental session
Blind broken
For Stage ll repeat CAPS, IES 
& SCL-90-R 2 months after 2nd
open lable MDMA session
*Subjects who received placebo in stage l
may elect to repeat above cycles for 2
open lable MDMA sessions
Repeat the above cycle for the
second
experimental session
There 90 minute non-drug
therapy sessions for
integration following each
experimental session
approximately weekly
Stage ll*
(open lablel
cross-over)
90 min session with therapists
next morning
Figure 2. Study Visits.
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experimental sessions.
In addition to experimental sessions of MDMA or placebo
during psychotherapy, the therapeutic intervention included
non-drug psychotherapy sessions for preparation and integra-
tion. A male and female co-therapist team, one a psychiatrist,
the other a psychiatric nurse, was present for all sessions.
Each subject had two 90-min introductory sessions within
6 weeks before the ﬁrst experimental session to prepare
them for the structure of the sessions, the approach to therapy
and possible eﬀects of MDMA. In Stage 1, there were eight
integration sessions focused on discussing the experimental
sessions, additional emotional processing (Foa and Kozak,
1986) if necessary, and helping subjects incorporate any
insights or new perspectives into their daily lives. One of
these integration sessions occurred the morning after each
of the two experimental sessions, and three more were sched-
uled during the month following each experimental session.
Additional integration sessions were permitted if needed. A
ﬁnal integration session occurred 2 months after the second
experimental session. In Stage 2, the schedule of integration
sessions was the same as in Stage 1 except that there were
three scheduled follow-up sessions after each experimental
session instead of four.
The method of psychotherapy followed principles
developed by Stanislav Grof, MD and others for LSD psy-
chotherapy (Pahnke et al., 1971) and Holotropic Breathwork
(Grof, 2000), and adapted for MDMA-assisted psychother-
apy by Metzner and others (Greer and Tolbert, 1998;
Metzner and Adamson, 2001). These methods were further
modiﬁed by the investigators for application to PTSD
treatment, and the psychotherapy technique was manualized
to the extent possible prior to this initial pilot study. This
draft treatment manual was written by the sponsor and inves-
tigators before the study began, and is being reﬁned and
operationalized with quantitative adherence measures based
on this pilot study. It is available at http://www.maps.org/
mdma/
During experimental sessions, the subject sat or reclined
on a futon bed and the co-therapists sat in chairs on either
side. The ﬁrst dose of MDMA (125mg) or placebo was
given in a capsule by mouth at 10a.m. Subjects then
rested in a comfortable position with eyes closed or wearing
eyeshades, and listened to a program of music that was ini-
tially relaxing and later emotionally evocative. The pro-
grams of music used were identical for all subjects, though
subjects or investigators could choose to skip over some
selections or to replace them with periods of silence.
Throughout the experimental sessions, periods of conversa-
tion alternated with periods during which subjects were
encouraged to focus on introspection. The schedule for
these alternating periods was ﬂexible and determined by
the desires of the subject and the judgment of the therapists.
The therapists sought an approximately equal balance
between quiet introspection and therapeutic discussion, but
the actual ratio varied among individuals and between
sessions.
The optional supplemental dose of 62.5mg MDMA or
placebo was administered 2–2.5h after the initial dose if
the investigators judged it to be safe and advisable and the
subject agreed to it. The supplemental dose was administered
in 22 of the 23 sessions in which it was an option. The
Table 1. Study Visits
Stage 1 
Visit number  1  2  3  4  5 6 7  8 9 10  11 12 13  14 15 16 17 
SCID
CAPS
X    
Medical 
evaluation
X    
CAPS
IES
SCL-90
RBANS
Rey 
PASAT
Preparatory 
psychotherapy 
MDMA or 
placebo 
Non-drug 
psychotherapy  
Stage 2, Open-label cross-over for placebo subjects   
Visit number  17.1  2–
18
2–
19
2–
20
2– 
21
2–
22
2–
23
2–
24
2–
25
2–26
CAPS
IES
SCL-90
X**      
Non-drug 
psychotherapy  
Non-drug psychotherapy sessions occurred 1–7 days apart.*3–7 days after prior MDMA or placebo session. Grey bars
indicate experimental sessions with MDMA or placebo.
Visit 5 occurred within a month after visit 1. Visit 11 occurred 3–5 weeks after visit 5. Visit 17 occurred 2 months after
visit 11. Non-drug psychotherapy sessions occurred 1–7 days apart. 
** Symptom measures repeated only if visit 18 occurred > 30 days after the final symptom measures in the double-blind
protocol, visit 17. ***2 months after second MDMA session. Visit 2-22 occurred 3–5 weeks after Visit 2-18.
MDMA
X
X
X XX
X
XX X
X
X
X
XX X X
X
X XXX
X
X
X X*
X*
X*
X***
444 Journal of Psychopharmacology 25(4)therapists stayed with the subject until at least 5p.m. or until
the physical and psychological eﬀects of the session had sub-
stantially subsided and the subject was judged to be in stable
condition and at baseline mental status. If necessary, zolpi-
dem or lorazepam were prescribed for insomnia. During
psychotherapy on the following day, participants and inves-
tigators were asked to guess condition assignment and rate
the certainty of their guess.
Statistical analysis
Per-protocol analysis with ANOVA with repeated measures
was conducted to test CAPS, IES-R and SCL-90-R scores for
diﬀerences between groups over time. The Holm’s sequential
Bonferroni correction for multiplicity was employed after a
signiﬁcant ANOVA for the four post-hoc tests for diﬀerences
between groups.
Results
Table 2 shows participant characteristics. Fifteen of the 20
subjects had previously undergone multiple medication
trials (mean 4.2 diﬀerent psychiatric drugs) and 15 had com-
pleted more than one course of psychotherapy. Average dura-
tionofPTSDwasestimatedat19þyears.Atbaselinetherewere
no signiﬁcant diﬀerences between groups with the exception
of duration of previous therapy. Analysis of co-variance
with repeated measures was conducted for CAPS using
numberofmonthsofprevioustherapyascovariate.Thecovar-
iate proved non-signiﬁcant (CAPS: F¼0.35, p¼0.56). Index
traumas for participants are shown in Table 3. Two subjects,
not included in Tables 2 or 3, dropped out before the second
experimental session. One did so because she required resump-
tion of medication for relapse of depression 42 days after her
one MDMA-assisted session. The other withdrew because
he found travel to the study site problematic due to limits on
reimbursement of travel expenses set by the IRB, which
were increased at the sponsor’s request after this subject
dropped out.
Physiological response and side effects
Onset of MDMA eﬀects occurred 45–75min after the initial
dose. The eﬀects reached a peak at 2–2.5h and lasted 4–5h in
the 11 subjects who received a single dose, and 5–6h in the
nine who received a supplemental dose. Eﬀects diminished
gradually over several hours. Elevations of blood pressure,
pulse, and body temperature were greater in the MDMA
group, and spontaneously returned to baseline at session
end in both groups (Table 4). There were no resulting medical
complications or pharmacologic interventions.
Table 2. Participant characteristics
CHARACTERISTIC All Subjects n¼20 MDMA group n¼12 Placebo Group n¼8 p
Mean age (std) 40.4 (7.2) 40.2 (7.6) 40.8 (7.0) 0.79
Gender 0.66
Male 3 15% 2 17% 1 13%
Female 17 85% 10 83% 7 87%
Caucasian 20 100% 12 100% 8 100%
Marital status 0.27
Never married 7 35% 6 50% 1 12.5%
Divorced/separated 2 10% 1 8% 1 12.5%
Widowed 1 5% 0 1 12.5%
Married/living with partner 10 50% 5 42% 5 62.5%
On disability for PTSD 3 15% 2 17% 1 13% 0.85
Hx alcohol abuse/dependency 2 10% 1 8% 1 13% 0.63
Hx other substance abuse/dependency 1 5% 0 1 12% 0.62
Prior MDMA use 9 43% 6 46% 3 38% 0.53
Lifetime MDMA use (number of times) for prior MDMA users 9 (1–5) 6 (1–5) 3 (1–2) 0.32
PTSD mean number of months of duration (std) 248 (173) 232 (201) 273 (126) 0.57
PTSD Crime-related 19 95% 11 85% 8 100% 0.60
PTSD War-related 1 5% 1 8% 0 0.60
Comorbid major depression 16 80% 9* 75% 7** 88% 0.47
Comorbid anxiety disorder 3 15% 2*** 17% 1**** 13% 0.65
Mean # months of prior therapy (std) 58.5 (49.5) 40.6 (38.5) 85.3 (54.2) 0.04
Mean Baseline CAPS score (std) 79.4 (22.4) 79.2 (23.6) 79.6 (22.0) 0.97
Bivariate statistical tests were conducted on all baseline measurements and subject characteristics to determine if significant differences existed initially between the
placebo and MDMA treatment groups. All tests were non-significant except number of months subjects had of previous therapy.
* two in remission
** three in remission
*** one panic disorder in remission, one current generalized anxiety disorder and simple phobia
**** current panic disorder and obsessive compulsive disorder, in remission
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of MDMA or placebo administration are shown in Table 5.
Themostcommonsideeﬀectsthatoccurredmorefrequentlyin
the MDMA group on the day of experimental sessions were:
jaw tightness, nausea, feeling cold, dizziness, loss of appetite,
andimpairedbalance.Equallyormorecommonintheplacebo
grouponthedayofexperimentalsessionswere:anxiety,insom-
nia, headache and fatigue. In the week following experimental
sessions,someofthemostcommonsideeﬀectswerereportedat
similar incidence by both groups: fatigue, anxiety, low mood,
headacheandnausea,withanxietybeingslightlymorefrequent
in the MDMA group and low mood slightly more frequent in
the placebo group. During this week, irritability and loss of
appetite were more frequently reported in the MDMA group
and insomnia was reported more often in the placebo group.
Side eﬀects typically resolved over a period of hours or days,
usually spontaneously; sometimes with short-term
symptomatic treatment such as sedative hypnotics or non-ster-
oidal anti-inﬂammatory drugs following experimental
sessions. No medical treatment was required during any exper-
imental sessions. No serious drug-related adverse eﬀects
occurred.
Symptom levels Stage 1 – double blind
Figure 3 illustrates that PTSD symptoms, as measured
by CAPS, improved over time in both groups (Time:
F(3, 17)¼40.292, p<0.0005), but the MDMA group
showed signiﬁcantly greater improvement (Time*Group
interaction F(1, 17)¼7.173, p¼0.015). Mean diﬀerences
between ‘group time’ were examined using independent
t-tests with Holm’s sequential Bonferroni correction (a)
for multiplicity. Statistical signiﬁcance (*) is indicated where
p<a: Time 1p¼0.966, a¼0.050, Time 2* p¼0.013,
a¼0.017, Time 3* p¼0.002, a¼0.012, Time 4* p¼0.013,
a¼0.025. Similar results were found for the IES-R, shown
in Figure 4. PTSD symptoms, as measured by IES-R,
improved over time in both groups (Time: F(3, 17)¼11.003,
p<0.0005), but the MDMA group showed signiﬁ-
cantly greater improvement (Time*Group interaction
F(1, 17)¼3.290, p¼0.027). Mean diﬀerences between ‘group-
 time’ were examined using independent t-tests with
Holm’s sequential Bonferroni correction (a) for multiplicity.
Statistically signiﬁcance (*) is indicated where p<a: Time
1p¼0.976, a¼0.050, Time 2* p¼0.016, a¼0.017, Time 3*
p¼0.006, a¼0.012, Time 4p¼0.038, a¼0.025. The CAPS
scores of the two subjects who dropped out, both of whom
were randomized to receive MDMA, fell from 110 and 107,
respectively, at baseline, to 17 and 27, respectively, 4 days
after their only MDMA-assisted psychotherapy session.
These data are not included in the analysis.
Table 4 Physiologic data: All experimental sessions
MDMA Placebo
Systolic BP Mean (St. Dev.) Range Mean (St. Dev). Range
Baseline 117.9 (15.0) 97/149 114.2 (11.6) 92/140
Maximum 143.1 (16.3) 117/179 136.4 (18.8) 102/176
Max Change 25.2 (13.7) 16/50 22.2 (15.3)  3/57
Diastolic BP
Baseline 74.6 (9.4) 56/92 74.4 (8.1) 58/89
Maximum 89.0 (9.2) 74/113 88.2 (10.5) 65/106
Max Change 14.4 (6.5) 1/14 13.8 (7.5) 2/28
Pulse
Baseline 74.3 (11.7) 54/98 69.9 (10.9) 5/92
Maximum 103.1 (15.9) 67/135 92.1 (17.8) 68/141
Max Change 28.8 (11.5)  7/52 22.2 (13.7) 3/57
Temperature
Baseline 36.6 (0.5) 35.6/37.8 36.3 (0.6) 35/37.2
Maximum 37.1 (0.3) 36.7/37.8 37.1(0.4) 36.7/37.8
Max Change 0.5 (0.4)  0.6/1.5  0.7 (0.6)  0.06/1.9
Group comparisons of vital signs were tested for change pre-session (15min prior) to highest recorded and pre-session to post-session (6h post) using t tests. There was a
significantly greater increase in all physiologic measures from pre-session to highest recorded value during experimental sessions for the MDMA group than for the placebo
group (p<0.05). There were no significant differences when comparing change from pre-session to post-session (p>0.05). All values returned to pre-session norms by 6h
after session completion.
Table 3. Index traumas for study participants
Index trauma MDMA (n¼12) Placebo (n¼8) p
Sexual assault 5 (42%) 3 (38%) p>0.95
Childhood abuse
Sexual 4 (33%) 4 (50%) p>0.95
Physical, neglect 2 (16%) 0 p¼0.35
Emotional 1 0 p>0.95
Family violence, other 1 0 p>0.95
Violence (as stabbing) 0 1 p>0.95
Combat stress 1 0 p>0.95
446 Journal of Psychopharmacology 25(4)Symptom levels Stage 2 – open-label crossover
Seven of the eight placebo subjects chose to enroll in the
crossover arm. One of the placebo responders, whose CAPS
score had fallen from 67 to 15 after placebo, elected not to
enroll in the crossover because she was satisﬁed with her
improvement. The other placebo responder had a transient
decline in CAPS from 54 to 15 after placebo, but her CAPS
increased to 64 in the 3 months prior to enrollment in Stage 2.
Paired t-tests were used to analyze change in outcome mea-
sures from Time 1c to Time 4c in the crossover arm. For the
seven placebo subjects who completed the open-label cross-
over, there were signiﬁcant decreases in CAPS (Table 6) and
IES-R scores (mean IES-R decrease¼15.9, SD¼12.1,
p¼0.013) from end of the control trial to 4–6 weeks after
two MDMA sessions were completed. These decreases are
similar in magnitude to the CAPS and IES-R decreases in
the subjects initially randomized to full-dose MDMA.
Neurocognitive measures
At baseline, there were no signiﬁcant group diﬀerences on any
of the cognitive measures including the RBANS total score
(t¼1.78, p¼0.09), PASAT Trial 1 (t¼0.95, p¼0.35),
PASAT Trial 2 (t¼ 0.16, p¼0.88) and the Rey-Osterrieth
Figure 30-minute delay (t¼0.06, p¼0.95). To test whether
the experimental condition had an adverse impact on cogni-
tion, between-group comparisons were performed at the
Table 5. Side effects: Number of instances of spontaneously reported side effects in association with both experimental sessions in Stage 1, with
instances a function of number of subjects and experimental sessions in which each side effect occurred during the session or within 7 days following
Day of MDMA
sessions (2)
Day of placebo
sessions (2)
Within 7 days
after MDMA sessions
Within 7 days after
placebo session
N (%) N (%) N (%) N (%)
Subjects¼12 Subjects¼8 Subjects¼12 Subjects¼8
Sessions N¼24 Sessions N¼16 Sessions N¼24 Sessions N¼16
Anxiety 14 (58%) 13 (81%) 13 (54%) 7 (44%)
Decreased concentration 3 (13%) 1 (6%) 6 (25%) 0
Derealization, detachment 0 0 1 (4%) 0
Diarrhea 0 0 3 (13%) 0
Dizziness 9 (38%) 2 (13%) 3 (13%) 1 (6%)
Drowsiness 2 (8%) 3 (19%) 0 2 (13%)
Dry mouth 4 (17%) 1 (6%) 1 (4%) 0
Fatigue 11 (46%) 8 (50%) 18 (75%) 12 (75%)
Feeling cold 10 (42%) 3 (19%) 1 (4%) 0
General infection 1 (4%) 0 0 2 (13%)
Headache 14 (58%) 9 (56%) 6 (25%) 4 (25%)
Heavy legs 2 (8%) 0 1 (4%) 0
Impaired balance 6 (25%) 0 0 0
Insomnia 13 (54%) 10 (63%) 9 (38%) 9 (56%)
Irritable 2 (8%) 3 (19%) 8 (33%) 3 (19%)
Loss of appetite 8 (33%) 1 (6%) 9 (38%) 0
Low mood 4 (17%) 2 (13%) 10 (42%) 8 (50%)
Muscle tension 4 (17%) 2 (13%) 2 (8%) 1 (6%)
Nausea 12 (50%) 2 (13%) 7 (29%) 4 (25%)
Need more sleep 0 1 (6%) 5 (21%) 2 (13%)
Nystagmus 1 (4%) 0 0 0
Pain 1(4%) 4 (25%) 1 (4%) 1 (6%)
Panic, re-experiencing 0 0 1 (4%) 1 (6%)
Parasthesias 2 (8%) 0 0 0
Perspiration 4 (17%) 1 (6%) 0 1 (6%)
Restless 5 (21%) 2 (13%) 1(4%) 0
Rumination 1 (4%) 1 (6%) 3 (13%) 2 (13%)
Somatic sensations 1 (4%) 1 (4%)
Thirst 2 (8%) 1 (6%) 0 0
Tight jaw 19 (79%) 3 (19%) 6 (25%) 2 (13%)
Upper GI burning 1 (4%) 0 0 0
Upper respiratory infection 0 0 2 (8%) 2 (13%)
Visual disturbance 1(4%) 0 2 (8%) 0
Weakness 1 (4%) 1 (6%) 6 (25%) 0
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sion. There were no signiﬁcant group diﬀerences on any of the
major index scores. This is best captured by the RBANS total
score (t¼1.05, p¼0.31), PASAT Trial 1 (t¼0.35, p¼0.19),
PASAT Trial 2 (t¼0.41, p¼0.69) and the Rey-Osterrieth
30-minute delay score (t¼0.98, p¼0.35).
Clinical response
Clinical response was deﬁned as >30% reduction from base-
line in CAPS total severity score. In Stage 1, the clinical
response was 83.3% (10/12) in the MDMA group versus
25% (2/8) in the placebo group. Likewise, 10 of the
MDMA group no longer met DSM-IV criteria for PTSD
compared with two of the placebo group. In Stage 2, the
clinical response rate was 100% in the seven subjects, six of
whom had failed to respond to placebo and one of whom had
relapsed after an initial placebo response. An unplanned
observation was that all three subjects who reported being
unable to work due to PTSD were able to return to work.
Additional psychotherapy sessions
As allowed in the protocol, additional psychotherapy sessions
occurred when the investigators judged them to be necessary
to support integration in subjects who experienced anxiety or
other diﬃculties following experimental sessions. Only one
additional session was conducted following placebo sessions,
whereas 20 such sessions were provided to seven of 13 sub-
jects following MDMA-assisted sessions. The data does not
allow meaningful statistical characterization of the relation-
ship between extra visits and changes in symptom measures;
for one to three extra sessions there was a trend toward cor-
relation with improved CAPS scores, but any increase beyond
three extra sessions was inversely related to improvement in
CAPS scores.
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Figure 4. IES-R Mean Scores by Group for Time 1-Time 4.
Table 6. Crossover Post-hoc Group Comparisons of CAPS at Time
1c–Time 4c
Crossover
Arm CAPS
Time 1c
(Baseline)* Time 4c**
Change Time
1c-Time 4c
MDMA Mean 65.6 33.9  31.7***
n 77 7
Std. Dev. 24.2 12.8 15.0
*Crossover Time 1c is pre-MDMA and at least 2 months post-placebo. Crossover trial
Time 4¼Time 1c, unless >30 days until starting crossover, in which case baseline
measures repeated <30 days before crossover.
**4–6 weeks after second MDMA session
*** p<0.05 Post-hoc paired t-test determined statistical significance of mean
difference between times
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Comparing CAPS scores over the four time periods between
the four subjects who received a supplemental dose of
MDMA (per protocol amendment) and the eight who did
not, there were no signiﬁcant diﬀerences in Group by
time (ANOVA with repeated measures F(1, 9)¼0.413,
p¼0.637).
Evaluation of blind
Nineteen of 20 participants (95%) correctly guessed their con-
dition assignment, though three were uncertain about their
guess. The therapists guessed correctly in all cases, but were
uncertain in three instances.
Rescue medication
Zolpidem was administered following 31 of 51 MDMA-
assisted sessions (60.7%) and after 11 of 16 psychotherapy-
only sessions (68.8%) (p¼0.77). Benzodiazepines were
administered following (though usually not the same day
as) 24 of 51 MDMA-assisted sessions (47.0%) and after six
of 16 psychotherapy-only sessions (37.5%) (p¼0.57 – both
with Fisher’s Exact Test). Seventeen of 20 subjects, the major-
ity of whom had pre-existing sleep disturbance related
to PTSD, received zolpidem for insomnia during study par-
ticipation. In ﬁve cases this was limited to one or two nights
following MDMA or placebo sessions. Fourteen sub-
jects received benzodiazepines during study participation.
Eleven of 14 reported taking benzodiazepines before enroll-
ment. Two of the three who had not taken benzodiaze-
pines before study enrollment did so for 1 and 7 days,
respectively. The mean decrease in CAPS scores from time
1 to time 4 was nearly equal for the 14 who received benzo-
diazepines and the six who did not: 40.3 (SD¼39) and 40.7
(SD¼27.2), respectively (p¼0.98).
Discussion
This pilot study demonstrates that MDMA-assisted psycho-
therapy with close follow-up monitoring and support can be
used with acceptable and short-lived side eﬀects in a carefully
screened group of subjects with chronic, treatment-resistant
PTSD. In this group, MDMA-assisted psychotherapy com-
pared with the same psychotherapy with inactive placebo pro-
duced clinically and statistically signiﬁcant improvements in
PTSD symptoms as measured by standard symptom scales.
This diﬀerence was immediate and was maintained through-
out the time period. There were no drug-related serious
adverse events and no evidence of impaired cognitive function
as measured by neuropsychological testing. The between-
group eﬀect size (1.24) of the study drug compares favorably
with other treatment modalities for PTSD (Foa et al., 2009),
particularly given the treatment-refractory nature of the cur-
rent sample. The clinical signiﬁcance of the symptom reduc-
tions is indicated by the high percentage of subjects attaining
a >30% reduction in CAPS scores and no longer meeting
criteria for PTSD 2 months after MDMA-assisted psycho-
therapy, and by the report that all three subjects who had
been unable to work because of PTSD were able to return
to work.
The strengths of this study are its prospective, double-
blind, crossover design, the use of a standardized primary
outcome measure (CAPS) that is widely used for PTSD
research (Weathers et al., 2001), enrollment of chronic, treat-
ment-resistant subjects who had moderate to severe PTSD,
and the use of a blinded, independent rater. Subjects met well-
deﬁned inclusion and exclusion criteria. Groups were well
matched; at baseline, subjects in both groups had nearly iden-
tical CAPS scores.
This study has several limitations and should be consid-
ered only a preliminary step toward exploring MDMA as a
possible therapeutic adjunct. Sample size is small, as is appro-
priate in a Phase II pilot study. The majority of participants
were female and all were Caucasian. Gender and/or ethnic
diﬀerences in response to MDMA-assisted psychotherapy
could exist. At baseline, the placebo group had a history
of more prior psychotherapy than the MDMA group,
which could mean that the placebo group was more treat-
ment-resistant; however, this covariate proved non-signiﬁ-
cant. Furthermore, in the open-label phase, the placebo
group had a response comparable to the MDMA group, so
in fact, the placebo group proved not to be more resistant to
MDMA-assisted psychotherapy.
Another important weakness of this study is the transpar-
ency of the blinding. We chose to use an inactive placebo in
this initial trial in order to compare side eﬀects of MDMA
with those of placebo in this patient population. Although the
independent rater remained eﬀectively blinded because he was
not present during experimental sessions, the novel subjective
experience was a strong clue for the subjects, as was the sub-
jects’ increase in pulse and blood pressure for the investiga-
tors. We have recently obtained a ‘may proceed’ letter from
the FDA for a protocol for a three-arm, dose–response study
that we expect will result in successful blinding. An argument
against a placebo response having accounted for between-
group outcome diﬀerences is the maintenance of treatment
eﬀect at 2-month follow-up, and the subjects’ having failed
to respond to prior treatments during a course of PTSD last-
ing a mean of nearly 20 years. Nevertheless, a placebo eﬀect
cannot be ruled out and future studies must address this
limitation.
Additional psychotherapy sessions were conducted more
often after MDMA-assisted sessions than after psychother-
apy-only sessions. This is a potentially confounding factor,
but it is not a likely explanation for the diﬀerence in ﬁnal
outcome. Additional psychotherapy cannot explain the sig-
niﬁcant improvements in CAPS scores recorded 4 days after
the ﬁrst MDMA-assisted session, before any additional psy-
chotherapy sessions occurred. In future studies, attempts
should be made to limit additional psychotherapy sessions
while retaining some ﬂexibility to ensure subject safety while
maintaining therapeutic eﬀect. Another limitation is that
measurement of the durability of symptom improvement
was limited to 2 months after the second experimental session.
We chose this interval because it is well beyond the acute
eﬀects of the drug and the immediate expectancy eﬀects, but
short enough to minimize eﬀects from intervening events.
A long-term outcome study is currently being conducted
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absence of therapist adherence measures was an unavoidable
weakness of this ﬁrst pilot study. A treatment manual and
adherence measures based on audio and video recordings
from this study have now been developed for use in future
clinical trials.
The use of zolpidem for sleep or benzodiazepines for
anxiety during the study did not diﬀer between the MDMA
and placebo conditions, but deserves some discussion to clar-
ify the intent. As is common with PTSD, most of the study
subjects had pre-existing sleep disturbance. Zolpidem was
oﬀered frequently, often the night after an experimental ses-
sion when subjects spent the night in the relatively unfamiliar
environment of the clinic after a long day of emotional pro-
cessing. Benzodiazepines were oﬀered more sparingly so as to
avoid suppressing ongoing emotional processing, which is
considered an important element of the integration phase
of therapy, while providing some symptomatic relief to help
subjects eﬀectively balance emotional processing with rest,
work and other daily activities. The vast majority of benzo-
diazepine doses went to people who had used them before,
and all subjects had previously taken psychiatric medications
with signiﬁcant anxiolytic properties that were not allowed
during the study. It is important to note that a temporary
increase in anxiety was sometimes a side eﬀect of this treat-
ment, but the fact that neither zolpidem nor benzodiazepines
were administered signiﬁcantly more often after MDMA
sessions than after placebo sessions suggests that this side
eﬀect was caused by the psychotherapy in the setting of
chronic PTSD rather than by MDMA administration.
An obvious feature of this treatment model is that it
involves an initial period of concentrated patient-therapist
contact (31h over 2 months) including all-day therapy ses-
sions and an overnight stay in the clinic. These are not usual
features of psychotherapy practice in the outpatient setting.
If MDMA-assisted psychotherapy is ultimately approved
for use in clinical practice, it would likely occur in clinics
speciﬁcally equipped for longer treatment sessions and over-
night stays. This method also involves patient preparation
and close follow-up to support further processing of emotions
and integration of cognitive shifts that may occur. Both the
preparation sessions and the integration sessions appear to
be important for safety and therapeutic eﬀect. In future stud-
ies we recommend that the number of 90-min preparation
sessions be increased from two to three. This approach is
initially more expensive than other outpatient treatments;
however, given the chronic nature of treatment-resistant
PTSD requiring ongoing psychiatric treatment and the asso-
ciated high rates of medical comorbidity and disability, it
has the potential to be more cost eﬀective over time for a
signiﬁcant segment of the patient population. In this study
the second session appeared to add depth to the overall
therapeutic process and it provided the reassurance that
subjects would have more than one opportunity to work
through their issues. Nevertheless, the fact that most of the
symptom improvement occurred after the ﬁrst MDMA-
assisted psychotherapy session suggests that it would be
worthwhile for future studies to investigate the impact of
number of sessions on strength and duration of PTSD symp-
tom reduction.
The promising results of this initial pilot study suggest that
further research is warranted to conﬁrm our ﬁndings, distin-
guish and reﬁne the essential elements of this approach,
enhance the methodology, and elucidate the mechanisms
involved.
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